Cipla Patalganga facility gets 6 USFDA observations
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
The regulator carried out a routine current Good Manufacturing Practices (cGMP) inspection from March 28 to April 4.
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
Venus Remedies' manufacturing unit, located in Baddi, Himachal Pradesh, has been recommended for supplying cephalosporin dry powder to UNICEF
ANVISA issues CGMP to Concord Biotech’s Unit I
The said Unit complies with the prescribed Good Manufacturing practices as per relevant WHO technical Report Series
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
InvaGen has received 5 inspectional observations in Form 483
Granules India received approval from Brazilian Health Regulatory Agency ANVISA
Subscribe To Our Newsletter & Stay Updated